The global contraceptive pills market size is projected to reach USD 20.55 billion by 2026, exhibiting a CAGR of 5.8% during the forecast period. High degree of unfulfilled contraceptive needs in rural areas in emerging economies is expected to be one of the key drivers for the growth of this market. Data gathered under the Demographic and Health Surveys (DHS) conducted between 2005 and 2014 in 52 developing countries revealed that around 8% to 38% of married rural women, aged between 15 and 49 years, faced unmet contraceptive needs. The main reason for this gap is the lack of accessibility and local availability of birth-control pills in these areas. To counter this, governments in many developing and underdeveloped countries are taking efforts to make these modern day medications more accessible and affordable to the rural populace. This will effectively accelerate the oral contraceptives market growth during the forecast period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contracept...

Expeditious Need to Curb Population Growth to Feed Market Development

According to the United Nations’ Department of Economic and Social Affairs, by 2030, world population will reach 8.6 billion and by 2050, it will be 9.8 billion. The prevalent anxiety is that such explosion of numbers will create wide socio-economic imbalances, especially in poor countries. Proactive measures are being taken by governments across the globe about family planning and use of the contraceptives to avoid unnecessary pregnancies. This desperate need to control population growth is expected to be one of the leading contraceptive pills market trends in the immediate future. Furthermore, increasing prevalence of teenage pregnancies, particularly in the U.S. has also emerged as a central factor driving the growth of this market.

Increasing Popularity of Advanced Contraceptives to Propel the Market in North America

North America is slated to dominate the contraceptive pills market share, since the region generated USD 4.09 billion in revenue in 2018. The primary reason for this is the rising uptake of short-acting reversible contraceptives in the U.S. and patient-friendly reimbursement policies for oral birth-control pills. Europe will emerge as the second leading region in this market, led by France which has the highest birth rate in the region. Better reimbursement policies will also bode well for the market in Europe. Asia-Pacific will record the fastest growth owing to rising number of awareness drives conducted by the government and NGOs. In Latin America, the Middle East, and Africa, increasing presence of big pharmaceutical companies and growing literacy rates will drive the market in these regions.